Ironwood Pharmaceuticals (IRWD) Shares Outstanding (Weighted Average) (2009 - 2026)

Ironwood Pharmaceuticals has disclosed Shares Outstanding (Weighted Average) across 18 years of filings, most recently posting $163.5 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $163.5 million, up 1.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $163.5 million (up 1.54% YoY), and the FY2025 annual result was $161.8 million, up 1.73% from the prior year.
• Shares Outstanding (Weighted Average) came in at $163.5 million for Q1 2026 at Ironwood Pharmaceuticals, up from $161.8 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $163.5 million in Q1 2026 to a low of $154.4 million in Q4 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $157.8 million (2022), against an average of $158.1 million.
• Across the five-year window, Shares Outstanding (Weighted Average) fell 4.93% in 2022 and climbed 2.65% in 2024, its largest moves.
• Ironwood Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $154.4 million in 2022, then grew by 0.69% to $155.4 million in 2023, then increased by 2.35% to $159.1 million in 2024, then climbed by 1.73% to $161.8 million in 2025, then gained by 0.99% to $163.5 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $163.5 million (Q1 2026), $161.8 million (Q4 2025), and $161.6 million (Q3 2025), per Business Quant data.